Skip to main content

Table 3 Compilation of malignancy risk stratification according to the EIF1AX mutation type and co-mutation profile from current study, Gargano et al. [11], and Karunamurthy et al. [2]

From: EIF1AX mutation in thyroid tumors: a retrospective analysis of cytology, histopathology and co-mutation profiles

 

Single mutation

Co-mutation

A113_Splice

12 Benign (57.1%)

1 Borderline (4.8%)

6 Malignant (28.6%)

2 Aggressive Malignant (9.5%)

14 Malignant (82.3%)

3 Aggressive Malignant (17.7%)

Non-A113_Splice

16 Benign (72.7%)

3 Borderline (13.6%)

3 Malignant (13.6%)

2 Benign (25%)

1 Borderline (12.5%)

5 Malignant (62.5%)

  1. A113_splice mutation had higher rates of malignancy, especially when present with co-mutations. Co-mutations in this analysis include RAS, TP53, TERT, YWHAG-BRAF fusion, PIK3CA
Back to article page

Journal of Otolaryngology - Head & Neck Surgery

ISSN: 1916-0216

Contact us